Owen Mumford, a global industry leader in medical device design and manufacturing based near Oxford, has appointed Professor Andrew Lewis as Research & Development Director as part of its continued investment in innovation.
Andrew is a Chartered Chemist and Fellow of The Royal Academy of Engineering as well as a Fellow of the Academy of Pharmaceutical Sciences. He is also a Visiting Professor of Biomaterials and Drug Delivery at the University of Brighton and has been recognised by the Pharmaceutical Society with an Excellence and Innovation Award.
Andrew has extensive experience within the technical and scientific field across a number of leading pharmaceutical and medical devices companies. Most recently, he led a global cross-platform team of technical heads as Vice President of R&D with Innovation at Boston Scientific, where he spearheaded multiple scientific collaborations with several highly-respected institutions including Edinburgh University.
Jarl Severn, Managing Director at Owen Mumford, says Andrew’s experience and knowledge will further support the company in ensuring innovation and scientific rigour are central to its R&D strategies:
“Andrew is extremely well-respected in the science and medical community as a regular conference speaker and contributor to scientific publications. He is known for developing R&D strategies and applying the latest management thinking to innovation pipelines focused on drug-device combinations. This innovative thinking will make him an invaluable asset to our company.”
Andrew joins Owen Mumford at an exciting time: “As a UK manufacturer, the company is launching a number of new devices designed to make the lives of health care professionals and patients safer and easier,” he says. “I’m looking forward to supporting and furthering Owen Mumford’s commitment to these critical safety goals.”